Rusquet R, Maniey D, Bassez T, David J C
Leuk Res. 1985;9(7):859-67. doi: 10.1016/0145-2126(85)90307-8.
Several widely used and experimental antileukemic drugs have been tested on the activity of Terminal deoxynucleotidyl Transferase (TdT) purified from normal human thymocytes and T-derived acute lymphoblastic leukemia peripheral blood lymphoblasts. The majority of these inhibitors were equally potent inhibitors of the enzyme from thymocytes or leukemic lymphocytes. Adriamycine and etoposide were more potent inhibitors of the enzyme purified from thymocytes. Vincristine was a more potent inhibitor of TdT extracted from leukemic lymphocytes than from thymocytes. These results are discussed in terms of possible functions for TdT in the two types of cells and on the value of TdT as an indicator for clinical treatment.
几种广泛使用的和实验性抗白血病药物已针对从正常人胸腺细胞和T细胞来源的急性淋巴细胞白血病外周血淋巴母细胞中纯化的末端脱氧核苷酸转移酶(TdT)的活性进行了测试。这些抑制剂中的大多数对来自胸腺细胞或白血病淋巴细胞的酶具有同等效力的抑制作用。阿霉素和依托泊苷对从胸腺细胞中纯化的酶是更强效的抑制剂。长春新碱对从白血病淋巴细胞中提取的TdT的抑制作用比对胸腺细胞中提取的TdT更强效。根据TdT在两种细胞类型中的可能功能以及TdT作为临床治疗指标的价值对这些结果进行了讨论。